Kidney Cancer Coverage from Every Angle

Recent News

Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma
AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer
AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer
Do Proton Pump Inhibitors Influence Cabozantinib Outcomes in Metastatic Kidney Cancer?
Two Perspectives on One Woman’s Successful Robotic Kidney-Sparing Surgery
Prognostic Role of Sarcopenia for Targeted Therapy in Metastatic Kidney Cancer
IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?
Tivozanib Versus Sorafenib in Refractory Renal Cell Carcinoma
CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma
Plasma KIM-1: Biomarker for Recurrence Risk After Surgery for Localized Kidney Cancer?
Advanced Renal Cell Carcinoma: Focus on Gender and Racial Differences in Treatment
FDA Grants Priority Review to HIF-2α Inhibitor for Renal Cell Carcinoma
Comparing Immunotherapy Regimens in Metastatic Kidney Cancer
FDA Approval Granted to Tivozanib for Advanced Renal Cell Carcinoma
GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer
GU Symposium 2021: Novel mTOR1/2 Inhibitor Under Study in Metastatic Kidney Cancer
Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma
GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer
Does Metastatic Tumor Shrinkage Influence Overall Survival in Renal Cell Carcinoma?
GU Symposium 2021: Cabozantinib Emerges From SWOG 1500 Trial of Metastatic Papillary Kidney Cancer
GU Symposium 2021: CLEAR Trial of Lenvatinib and Pembrolizumab or Everolimus in Kidney Cancer
Impact of the Affordable Care Act in Renal Cell Carcinoma
GU Symposium 2021: Oral HIF-2α Inhibitor Plus Cabozantinib in Advanced Kidney Cancer
GU Symposium 2021: Cabozantinib for Renal Cell Carcinoma With Brain Metastases
After Cytoreductive Nephrectomy: When Is More Treatment of Benefit?
Venous Thromboembolism at the Time of Surgery for a Renal Mass: Clinical Implications
Novel HIF-2α Inhibitor Under Study in Von Hippel-Lindau–Associated Kidney Cancer
Surgical Margin Status and Outcomes After Radical Nephrectomy
Impact of Surgical Treatment Delay on Outcomes in Renal Cell Carcinoma
Impact of Bone Metastases on Surgical Outcomes in Metastatic Kidney Cancer
SORCE Trial: Active Surveillance or Sorafenib After Surgery in Renal Cell Carcinoma?
Cabozantinib Plus Immunotherapy Under Study in Advanced Renal Cell Carcinoma
Nivolumab Plus Cabozantinib Approved by FDA for Advanced Renal Cell Carcinoma
Germline Mutations in Early-Onset Renal Cell Carcinoma
Immunotherapy After Nephrectomy Under Study in Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma: Dosage Studies of HIF-2α Inhibitor Underway
HIF-2α Inhibitor for von Hippel-Lindau Disease-Associated Clear Cell Kidney Cancer
Preclinical Study Examines Role of circRNA_001287 in Progression of Renal Cell Carcinoma
Palliative Care Utilization Trends in Advanced Renal Cell Carcinoma
Renal Cell Carcinoma and COVID-19: Does Surgical Delay Impact Outcomes?
Novel Glycolysis-Related Gene Signature Developed in Renal Cell Carcinoma
Case Study of Rare but Aggressive Immune-Related Adverse Events in Kidney Cancer
Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: OMNIVORE Trial

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.